Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes
about
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospectsComparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytesThe dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis.Current challenges and trends in the discovery of agrochemicals.A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.Discontinued in 2013: diabetic drugs.Functional analysis and transcriptional output of the Göttingen minipig genome.The NEIGHBOR consortium primary open-angle glaucoma genome-wide association study: rationale, study design, and clinical variablesCardiometabolic interventions - focus on transcriptional regulators.A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.Examining the safety of PPAR agonists - current trends and future prospects.Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.Analysis of PPAR-α/γ Activity by Combining 2-D QSAR and Molecular Simulation.Molecular modelling study of the PPARγ receptor in relation to the mode of action/adverse outcome pathway framework for liver steatosis.Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.Frontiers in Medicinal Chemistry 2009--a summary of the meeting at Heidelberg University.SAR and Computer-Aided Drug Design Approaches in the Discovery of Peroxisome Proliferator-Activated ReceptorγActivators: A Perspective
P2860
Q26829098-905F5604-DED5-4D9C-81CB-D81F97F194F6Q28730590-72CFA43B-90D0-4E07-8E69-504A72DA0D87Q33562214-E4739710-2CF7-411D-AC50-95AE941ADC2AQ34364424-BAE7BA07-518E-4F85-8212-3E8A9B6F6CE0Q34527082-C6842326-196B-4F33-BC7A-EC2DE60A496CQ34567151-F28E077A-76D5-4164-A33E-BD643377F666Q34618210-5DE91681-01E8-4B0D-B0A5-E5C361503C7DQ34628781-8A26CA34-8FF6-4AD6-9A2C-A5F3001E908DQ34664870-46FA775F-1A08-4D8D-AF06-0942303FA774Q35843080-1027BA94-E619-4D0F-BA90-DB50A3509580Q36360724-835F07C3-E79B-4715-80AB-B176C7901E54Q37161933-85D342C9-7B91-48B7-88B5-12CD9001D8DFQ37556648-F961845E-3B5E-48C2-BD60-7558CBA801A8Q37638828-B45D880B-CDB9-4B2A-95C0-9084B2232001Q38058381-2E7A6690-5134-4E36-B3A6-D4419BB52072Q39367068-2656715A-995D-4446-A9CF-68563EE45CE8Q39535351-4B846A54-0843-4620-B4C0-E65CF5521028Q40709802-6DE0A41F-21FF-49ED-A59E-59C6D249CAE6Q44692555-35B3C6AA-C105-4CF5-BA00-CDA3FFB77440Q51829072-AFE4AFCC-B715-41C3-8D2B-A1F136380253Q58919671-97074A84-4F3E-4245-8C8E-C291E5964752
P2860
Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Aleglitazar, a new, potent, an ...... treatment of type II diabetes
@ast
Aleglitazar, a new, potent, an ...... treatment of type II diabetes
@en
Aleglitazar, a new, potent, an ...... treatment of type II diabetes
@nl
type
label
Aleglitazar, a new, potent, an ...... treatment of type II diabetes
@ast
Aleglitazar, a new, potent, an ...... treatment of type II diabetes
@en
Aleglitazar, a new, potent, an ...... treatment of type II diabetes
@nl
prefLabel
Aleglitazar, a new, potent, an ...... treatment of type II diabetes
@ast
Aleglitazar, a new, potent, an ...... treatment of type II diabetes
@en
Aleglitazar, a new, potent, an ...... treatment of type II diabetes
@nl
P2093
P1476
Aleglitazar, a new, potent, an ...... treatment of type II diabetes
@en
P2093
Agnes Bénardeau
Alfred Binggeli
Bernd Kuhn
Daniel Schlatter
Denise Blum
Hans Hilpert
Hans Peter Märki
Kurt Püntener
P304
P356
10.1016/J.BMCL.2009.03.036
P407
P577
2009-05-01T00:00:00Z